961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy
Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Stéphane Dalle(Hospices Civils de Lyon), Luis de la Cruz‐Merino, Sonia Maciá(Highlight Therapeutics (Spain)), Miguel F. Sanmamed(Clinica Universidad de Navarra), R. Martín Huertas(Hospital Clínic de Barcelona), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Juan Francisco Rodríguez-Moreno(Hospital Universitario HM Sanchinarro), Marisol Quintero(Highlight Therapeutics (Spain)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Delvys Rodríguez‐Abreu(Universidad de Las Palmas de Gran Canaria), H. Montaudié(Centre Hospitalier Universitaire de Nice), Eva Muñoz‐Couselo(Vall d'Hebron Hospital Universitari), Juan Martín-Liberal(Institut d'Investigació Biomédica de Bellvitge), Elisa Funk-Brentano(Hôpital Ambroise-Paré), M.P. Lopez Criado(MD Anderson Cancer Center Madrid), Alfonso Berrocal(Hospital General Universitario De Valencia), Helena Escuin-Ordinas(University of California, Los Angeles), J. Charles(Apple (Israel)), Caroline Robert(Institut Gustave Roussy), Javier Sánchez López(Highlight Therapeutics (Spain)), Enrique de Miguel(Hospital General Universitario Gregorio Marañón), María González Cao(Hospital Universitario Dexeus), Pablo Cerezuela‐Fuentes(Hospital Universitario Virgen de la Arrixaca), Ana Arance(Hospital Clínic de Barcelona), Eduardo Castañón Álvarez(Clinica Universidad de Navarra), S. Prey(Université de Bordeaux)
Cited by 8
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k